NCT03835520View on ClinicalTrials.gov

Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

May 31, 2028

Study Completion Date

May 1, 2028

Conditions
Cancer
Interventions
DRUG

Immunotherapeutic Agent

Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.

DRUG

Molecular Target

Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.

Trial Locations (1)

1200

Cliniques Universitaires Saint-Luc, Brussels

All Listed Sponsors
lead

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

NCT03835520 - Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy | Biotech Hunter | Biotech Hunter